Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...
Good afternoon, and welcome to Castle Biosciences DecisionDx-Melanoma Webcast. As a reminder, today's webcast is being recorded. Drs. Guenther and Goldberg will begin with a presentation that follows ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a poster presentation on ...
Highlights From the 2025 Pediatric Oncology East and Mediterranean Biennial Conference: Advancing Pediatric Oncology Across the Eastern Mediterranean Breast cancer imposes a substantial disease burden ...
Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new ...
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score(R) ...
(RTTNews) - Castle Biosciences, Inc. (CSTL), Wednesday said that its DecisionDx-Melanoma test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA).
DecisionDx-SCC test predicts local recurrence and metastasis in high-risk cutaneous squamous cell carcinoma, enhancing personalized treatment decisions. The test categorizes patients into three risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results